Fig. 3From: Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradicationThe Helicobacter pylori eradication rates in susceptibility-guided therapy and empirical vonoprazan-based triple therapy. The differences in the eradication rates between these two therapies (susceptibility-guided therapy minus vonoprazan-based therapy) were 1.9% in the intention-to-treat analysis and − 1.7% in the per-protocol analysisBack to article page